CN107427515B - 用于治疗癌症的激酶抑制剂前药 - Google Patents

用于治疗癌症的激酶抑制剂前药 Download PDF

Info

Publication number
CN107427515B
CN107427515B CN201580075139.5A CN201580075139A CN107427515B CN 107427515 B CN107427515 B CN 107427515B CN 201580075139 A CN201580075139 A CN 201580075139A CN 107427515 B CN107427515 B CN 107427515B
Authority
CN
China
Prior art keywords
cancer
administration
egfr
cetuximab
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580075139.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN107427515A (zh
Inventor
A·V·帕特森
J·B·斯梅勒
S·席尔瓦
C·P·吉斯
M·R·布尔
V·杰克森
T·皮尔斯
N·达瓦尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Priority to CN202111320133.3A priority Critical patent/CN114224894B/zh
Publication of CN107427515A publication Critical patent/CN107427515A/zh
Application granted granted Critical
Publication of CN107427515B publication Critical patent/CN107427515B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580075139.5A 2014-12-03 2015-12-03 用于治疗癌症的激酶抑制剂前药 Active CN107427515B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111320133.3A CN114224894B (zh) 2014-12-03 2015-12-03 用于治疗癌症的激酶抑制剂前药

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462087212P 2014-12-03 2014-12-03
US62/087,212 2014-12-03
US201562150729P 2015-04-21 2015-04-21
US62/150,729 2015-04-21
US201562167849P 2015-05-28 2015-05-28
US62/167,849 2015-05-28
US201562187750P 2015-07-01 2015-07-01
US62/187,750 2015-07-01
PCT/US2015/063806 WO2016090174A1 (en) 2014-12-03 2015-12-03 Kinase inhibitor prodrug for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111320133.3A Division CN114224894B (zh) 2014-12-03 2015-12-03 用于治疗癌症的激酶抑制剂前药

Publications (2)

Publication Number Publication Date
CN107427515A CN107427515A (zh) 2017-12-01
CN107427515B true CN107427515B (zh) 2021-11-16

Family

ID=56092487

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580075139.5A Active CN107427515B (zh) 2014-12-03 2015-12-03 用于治疗癌症的激酶抑制剂前药
CN202111320133.3A Active CN114224894B (zh) 2014-12-03 2015-12-03 用于治疗癌症的激酶抑制剂前药

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111320133.3A Active CN114224894B (zh) 2014-12-03 2015-12-03 用于治疗癌症的激酶抑制剂前药

Country Status (6)

Country Link
US (1) US10507210B2 (enExample)
EP (1) EP3226869A4 (enExample)
JP (1) JP6769962B2 (enExample)
CN (2) CN107427515B (enExample)
AU (1) AU2015358384B2 (enExample)
WO (1) WO2016090174A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311858B (zh) 2016-05-26 2021-12-03 里科瑞尔姆Ip控股有限责任公司 Egfr抑制剂化合物
KR102323255B1 (ko) * 2017-02-15 2021-11-08 다이호야쿠힌고교 가부시키가이샤 의약 조성물
SG11202002060XA (en) 2017-09-08 2020-04-29 Univ Colorado Regents Compounds, compositions and methods for treating or preventing her-driven drug-resistant cancers
US12280045B2 (en) 2017-09-08 2025-04-22 Taiho Pharmaceutical Co., Ltd. Antitumor agent and antitumor effect potentiator
ES2935729T3 (es) * 2017-09-14 2023-03-09 Lankenau Inst Medical Res Métodos y composiciones para el tratamiento del cáncer
WO2019125184A1 (en) * 2017-12-19 2019-06-27 Auckland Uniservices Limited Use of biomarker in cancer therapy
KR20210066819A (ko) * 2018-09-04 2021-06-07 레인 세러퓨틱스 인코포레이티드 Her-유도 암을 치료 또는 예방하기 위한 화합물, 조성물 및 방법
WO2020084347A2 (en) * 2018-10-26 2020-04-30 Auckland Uniservices Combination of a kinase inhibitor and an immunotherapeutic agent, compositions and methods comprising the same
WO2020102304A1 (en) * 2018-11-13 2020-05-22 Rain Therapeutics Inc. Combination of a kinase inhibitor and an electrolyte, compositions and methods comprising the same
TW202039002A (zh) * 2018-12-07 2020-11-01 斯坦福大學托管董事會 缺氧標靶組成物及其與一parp抑制劑之組合以及此等的使用方法
MX2021010265A (es) * 2019-02-26 2021-09-23 Janssen Biotech Inc Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102574846A (zh) * 2009-09-02 2012-07-11 奥克兰联合服务有限公司 激酶抑制剂、其前药形式及它们在治疗中的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
WO1995011995A1 (en) 1993-10-26 1995-05-04 Affymax Technologies N.V. Arrays of nucleic acid probes on biological chips
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
US6228575B1 (en) 1996-02-08 2001-05-08 Affymetrix, Inc. Chip-based species identification and phenotypic characterization of microorganisms
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
BRPI0912170A2 (pt) * 2008-05-13 2015-10-13 Astrazeneca Ab composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
AU2010221818A1 (en) 2009-03-11 2011-10-06 Auckland Uniservices Limited Prodrug forms of kinase inhibitors and their use in therapy
WO2011146945A2 (en) * 2010-05-21 2011-11-24 Cell Signaling Technology, Inc. Alk and ros kinase in cancer
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
EP2736895B1 (en) * 2011-07-27 2016-01-06 Astrazeneca AB 2-(2,4,5-substituted-anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
AU2013347962B2 (en) * 2012-11-21 2018-10-25 Janssen Biotech, Inc. Bispecific EGFR/c-Met antibodies
CN105073116A (zh) * 2013-03-14 2015-11-18 辉瑞大药厂 治疗非小细胞肺癌的egfr t790m 抑制剂与egfr 抑制剂的组合
EP2983591A4 (en) 2013-04-10 2016-12-28 Threshold Pharmaceuticals Inc PREDICTIVE AND RESPONSE BIOMARKERS FOR TH-302 CANCER THERAPY

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102574846A (zh) * 2009-09-02 2012-07-11 奥克兰联合服务有限公司 激酶抑制剂、其前药形式及它们在治疗中的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"2-羟丙基-β-环糊精对羟基喜树碱的增溶及稳定作用研究";宋金春;《中国药房》;20080210 *
"PR610: A novel hypoxia selective tyrosine kinase inhibitor in phase 1 clinical trial";Adam V Patterson;《Molecular cancer therapeutics》;20131130;第12卷(第SUPPL 期) *

Also Published As

Publication number Publication date
CN107427515A (zh) 2017-12-01
WO2016090174A1 (en) 2016-06-09
US20170360790A1 (en) 2017-12-21
EP3226869A1 (en) 2017-10-11
CN114224894B (zh) 2025-01-07
AU2015358384B2 (en) 2021-03-04
JP2017536408A (ja) 2017-12-07
JP6769962B2 (ja) 2020-10-14
EP3226869A4 (en) 2018-07-18
AU2015358384A1 (en) 2017-06-29
US10507210B2 (en) 2019-12-17
CN114224894A (zh) 2022-03-25

Similar Documents

Publication Publication Date Title
CN107427515B (zh) 用于治疗癌症的激酶抑制剂前药
US20230146638A1 (en) Treatment of EGFR-Driven Cancer with Fewer Side Effects
US11395821B2 (en) Treatment of EGFR-driven cancer with fewer side effects
US20170321281A1 (en) Methods and compositions for treatment of glioblastoma
CN115867669A (zh) 监测kras突变的方法
WO2022020281A1 (en) Combination therapy with a mutant idh1 inhibitor, a deoxyadenosine analog, and a platinum agent
Kang et al. A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17)
BR112021011493A2 (pt) Terapia de combinação para tratamento de câncer
RU2496499C2 (ru) Оптимизация индивидуальных доз 5-фторурацила при режиме folfiri
WO2023183354A1 (en) Blu-945 in combination with osimertinib for the treatment of non-small-cell lung cancer
JP2025508399A (ja) 脳がんの処置のためのニラパリブの使用
US12144813B2 (en) PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
US20260069596A1 (en) Use of plk1 inhibitor as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancer
WO2025232765A1 (en) Treatment of cancer with pyrimidoheterocyclic compounds
US11058702B2 (en) Methods and compositions for the treatment of cancer with 5-iodo-2-pyrimidinone-2′-deoxyribose (IPdR)
US11149300B1 (en) Methods of treating gastrointestinal malignancies
Vita et al. 1363P Genomic heterogeneity of ALK rearrangements and acquired resistance pathways in ALK+ Advanced non-small cell lung cancer (NSCLC) treated with upfront alectinib: Preliminary results of GALILEO project
TW202604516A (zh) 用嘧啶雜環化合物治療癌症
US20110312981A1 (en) Predictive marker for egfr inhibitor treatment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant